Amyloid β1−40

There are 2 papers on amyloid β1−40 in aging research: 1 trial and 1 observational study in people.

Biomarker

2 papers study it3 findings

See all 2 papers on amyloid β1−40

“and in Aβ1-40 (-52.1, -40.3, and -50.7% vs. -30.7%, P < 0.05).”
GLP-1 receptor agonists, SGLT-2 inhibitors, and their combination: effects on carotid atherosclerosis regression, oxidative stress, and amyloid-β1-40 in diabetesAmerican journal of physiology. Heart and circulatory physiology2026doi:10.1152/ajpheart.00996.2025
  • Human trial1
  • Humans1

Associations

3

Liraglutide + empagliflozin

downin humans1

1 study
  1. Liraglutide + empagliflozin is associated with amyloid β1−40 in humans (Metformin-treated type 2 diabetes; compared with insulin) (-50.7% versus -30.7% with insulin).

    HumansMetformin-treated type 2 diabetes; compared with insulinplasma12 monthsn = 183

More on Liraglutide + empagliflozin

Empagliflozin

downin humans1

1 study
  1. Empagliflozin is associated with amyloid β1−40 in humans (Metformin-treated type 2 diabetes; compared with insulin) (-40.3% versus -30.7% with insulin).

    HumansMetformin-treated type 2 diabetes; compared with insulinplasma12 monthsn = 183

More on Empagliflozin

Liraglutide

downin humans1

1 study
  1. Liraglutide is associated with amyloid β1−40 in humans (Metformin-treated type 2 diabetes; compared with insulin) (-52.1% versus -30.7% with insulin).

    HumansMetformin-treated type 2 diabetes; compared with insulinplasma12 monthsn = 183

More on Liraglutide

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months